151 related articles for article (PubMed ID: 21229)
1. The interactions of bromocriptine and lergotrile with dopamine and alpha-adrenergic receptors.
Lew JY; Hata F; Ohashi T; Goldstein M
J Neural Transm; 1977; 41(2-3):109-21. PubMed ID: 21229
[TBL] [Abstract][Full Text] [Related]
2. Binding interactions of ergot alkaloids with monoaminergic receptors in the brain.
Goldstein M; Lew JY; Hata F; Lieberman A
Gerontology; 1978; 24 Suppl 1():76-85. PubMed ID: 22480
[TBL] [Abstract][Full Text] [Related]
3. Bromocriptine, lergotrile: the antiparkinsonian efficacy and the interaction with monoaminergic receptors.
Goldstein M; Lieberman A; Battista AF; Lew JY; Hata F
Pharmacology; 1978; 16 Suppl 1():143-9. PubMed ID: 25445
[TBL] [Abstract][Full Text] [Related]
4. Is inhibition of striatal synaptosomal tyrosine hydroxylation by dopamine agonists a measure of dopamine autoreceptor function?
Fowler CJ; Thorell G; Andersson M; Magnusson O
Naunyn Schmiedebergs Arch Pharmacol; 1985 Oct; 331(1):12-9. PubMed ID: 2866447
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of three dopamine agonists: apomorphine, bromocriptine and lergotrile.
Silbergeld EK; Pfeiffer RF
J Neurochem; 1977 Jun; 28(6):1323-6. PubMed ID: 577501
[No Abstract] [Full Text] [Related]
6. Antagonistic effects of apomorphine and haloperidol on rat striatal synaptosomal tyrosine hydroxylase.
Christiansen J; Squires RF
J Pharm Pharmacol; 1974 May; 26(5):367-9. PubMed ID: 4152779
[No Abstract] [Full Text] [Related]
7. Characterization of dopamine receptors mediating inhibition of adenylate cyclase activity in rat striatum.
Onali P; Olianas MC; Gessa GL
Mol Pharmacol; 1985 Aug; 28(2):138-45. PubMed ID: 2410769
[TBL] [Abstract][Full Text] [Related]
8. [3H]dihydroergocryptine binding in rat brain.
Davis JN; Strittmatter WJ; Hoyler E; Leefkowitz RJ
Brain Res; 1977 Aug; 132(2):327-36. PubMed ID: 196714
[TBL] [Abstract][Full Text] [Related]
9. Stereotyped responses of rats to two 2-halogenoergolines: 2-bromo-alpha-ergocryptine and lergotrile.
Bergmann F
Isr J Med Sci; 1982 Jan; 18(1):177-82. PubMed ID: 6121772
[TBL] [Abstract][Full Text] [Related]
10. Action of apomorphine, bromocriptine and lergotrile on gamma-aminobutyric acid and acetylcholine release in nucleus accumbens and corpus striatum.
de Belleroche J; Gardiner IM
J Neural Transm; 1983; 58(3-4):153-68. PubMed ID: 6141217
[TBL] [Abstract][Full Text] [Related]
11. Dopamine receptors in the central nervous system.
Seeman P; Tedesco JL; Lee T; Chau-Wong M; Muller P; Bowles J; Whitaker PM; McManus C; Tittler M; Weinreich P; Friend WC; Brown GM
Fed Proc; 1978 Feb; 37(2):131-6. PubMed ID: 414936
[TBL] [Abstract][Full Text] [Related]
12. Central monoamine synapses as sites of action for ergot drugs.
Fuxe K; Ogren SO; Agnati LF; Andersson K; Hall H; Köhler C; Fredholm B
Adv Biochem Psychopharmacol; 1980; 23():41-62. PubMed ID: 6104914
[TBL] [Abstract][Full Text] [Related]
13. Effects of agonists and antagonists of D1 and D2 dopamine receptors on self-stimulation of the medial prefrontal cortex in the rat.
Ferrer JM; Sanguinetti AM; Vives F; Mora F
Pharmacol Biochem Behav; 1983 Aug; 19(2):211-7. PubMed ID: 6138775
[TBL] [Abstract][Full Text] [Related]
14. Ergot alkaloids: interaction with presynaptic dopamine receptors in the neostriatum and olfactory tubercles.
Marek KL; Roth RH
Eur J Pharmacol; 1980 Mar; 62(2-3):137-46. PubMed ID: 6769681
[TBL] [Abstract][Full Text] [Related]
15. Differential behavioral and biochemical effects of four dopaminergic agonists.
Gianutsos G; Moore KE
Psychopharmacology (Berl); 1980; 68(2):139-46. PubMed ID: 6107946
[TBL] [Abstract][Full Text] [Related]
16. Characterization of normal and supersensitive dopamine receptors: effects of ergot drugs and neuropeptides.
Fuxe K; Agnati LF; Köhler C; Kuonen D; Ogren SO; Andersson K; Hökfelt T
J Neural Transm; 1981; 51(1-2):3-37. PubMed ID: 7264628
[TBL] [Abstract][Full Text] [Related]
17. The effect of butaclamol and of other neuroleptic agents on the apomorphine-elicited inhibition of synaptosomal tyrosine hydroxylase activity.
Bronaugh RL; Tabak J; Ohashi T; Goldstein M
Psychopharmacol Commun; 1975; 1(5):501-10. PubMed ID: 7003
[TBL] [Abstract][Full Text] [Related]
18. Neurochemical effects of some ergot derivatives: a basis for their antiparkinson actions.
Markstein R
J Neural Transm; 1981; 51(1-2):39-59. PubMed ID: 6267192
[TBL] [Abstract][Full Text] [Related]
19. Rotational behaviour in rats with unilateral striatal kainic acid lesions: a behavioural model for studies on intact dopamine receptors.
Schwarcz R; Fuxe K; Agnati LF; Hökfelt T; Coyle JT
Brain Res; 1979 Jul; 170(3):485-95. PubMed ID: 37986
[TBL] [Abstract][Full Text] [Related]
20. Dopaminergic modulation of hippocampal noradrenaline release. Evidence for alpha 2-antagonistic effects of some dopamine receptor agonists and antagonists.
Jackisch R; Moll S; Feuerstein TJ; Hertting G
Naunyn Schmiedebergs Arch Pharmacol; 1985 Aug; 330(2):105-13. PubMed ID: 2995843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
